Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging
Joana Dias, … , John R. Mascola, Richard A. Koup
Joana Dias, … , John R. Mascola, Richard A. Koup
Published September 1, 2021
Citation Information: J Clin Invest. 2021;131(17):e151632. https://doi.org/10.1172/JCI151632.
View: Text | PDF
Research Article AIDS/HIV Immunology

Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging

  • Text
  • PDF
Abstract

Primary HIV-1 infection can be classified into six Fiebig stages based on virological and serological laboratory testing, whereas simian-HIV (SHIV) infection in nonhuman primates (NHPs) is defined in time post-infection, making it difficult to extrapolate NHP experiments to the clinics. We identified and extensively characterized the Fiebig-equivalent stages in NHPs challenged intrarectally or intravenously with SHIVAD8-EO. During the first month post-challenge, intrarectally challenged monkeys were up to 1 week delayed in progression through stages. However, regardless of the challenge route, stages I–II predominated before, and stages V–VI predominated after, peak viremia. Decrease in lymph node (LN) CD4+ T cell frequency and rise in CD8+ T cells occurred at stage V. LN virus-specific CD8+ T cell responses, dominated by degranulation and TNF, were first detected at stage V and increased at stage VI. A similar late elevation in follicular CXCR5+ CD8+ T cells occurred, consistent with higher plasma CXCL13 levels at these stages. LN SHIVAD8-EO RNA+ cells were present at stage II, but appeared to decline at stage VI when virions accumulated in follicles. Fiebig-equivalent staging of SHIVAD8-EO infection revealed concordance of immunological events between intrarectal and intravenous infection despite different infection progressions, and can inform comparisons of NHP studies with clinical data.

Authors

Joana Dias, Giulia Fabozzi, Kylie March, Mangaiarkarasi Asokan, Cassandra G. Almasri, Jonathan Fintzi, Wanwisa Promsote, Yoshiaki Nishimura, John-Paul Todd, Jeffrey D. Lifson, Malcolm A. Martin, Lucio Gama, Constantinos Petrovas, Amarendra Pegu, John R. Mascola, Richard A. Koup

×

Figure 1

Study design and kinetics of SHIVAD8-EO infection in rhesus macaques.

Options: View larger image (or click on image) Download as PowerPoint
Study design and kinetics of SHIVAD8-EO infection in rhesus macaques.
(A...
(A) Twelve rhesus macaques were challenged either intrarectally (n = 6) or intravenously (n = 6) with 1000 or 100 TCID50 of SHIVAD8-EO, respectively, and sampled at different time points during the course of the infection. The orange arrow indicates challenge with SHIVAD8-EO, and the red and blue squares indicate time points of blood sampling and LN collection, respectively. (B) Plasma viral load up to 20 weeks post-challenge in the monkeys challenged with SHIVAD8-EO via the i.r. (left) or i.v. (right) route. (C) Time to first detectable plasma virus (left) and to peak plasma viremia (right) upon i.r. or i.v. challenge with SHIVAD8-EO. (D and E) Plasma viral load throughout the first 20 weeks after SHIVAD8-EO challenge as determined by area under the curve (AUC) analysis (D), and at the peak time point (left) and 20 weeks post-challenge (right) (E). Bar graphs show the mean ± SEM and individual data points (C–E). The Mann-Whitney test was used to detect significant differences between each 2 groups with unpaired samples (C–E). *P < 0.05; **P < 0.01. i.r., intrarectal; i.v., intravenous; NHP, nonhuman primate; pc, post-challenge.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts